1800-272-662
Shopping Cart 0
countryflagAU
Login

Next Science Ltd

Healthcare AU NXS

NoneAUD
-(-%)

Last update at 2026-03-11T06:45:05.996063Z

Day Range

--
LowHigh

52 Week Range

0.060.15
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap42.43M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.21763M
  • Revenue TTM22.07M
  • Revenue Per Share TTM0.08
  • Gross Profit TTM 18.20M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -10.58602M -16.27081M -12.68331M -9.34964M -11.91200M
Minority interest - - - - -
Net income -10.58602M -24.51287M -11.83417M -9.35718M -11.83649M
Selling general administrative 6.75M 5.61M 5.39M 3.91M 3.14M
Selling and marketing expenses 16.07M 20.17M 10.31M 7.37M 5.65M
Gross profit 18.44M 16.23M 9.15M 6.94M 2.92M
Reconciled depreciation 1.27M 1.11M 0.90M 0.79M 0.91M
Ebit -10.30208M -15.53490M -13.54834M -9.59997M -12.52074M
Ebitda -9.02885M -14.42188M -12.65124M -8.80969M -11.81915M
Depreciation and amortization 1.27M 1.11M 0.90M 0.79M 0.70M
Non operating income net other - - - - -
Operating income -10.30411M -15.95408M -13.54834M -9.59997M -12.52074M
Other operating expenses 33.12M 38.13M 25.31M 18.56M 15.97M
Interest expense 0.28M 0.74M -0.01588M 1.04M 0.61M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.04M 0.47M 0.01M 0.13M 0.14M
Net interest income -0.28191M -0.31673M -0.01588M 0.00004M 0.11M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.00000M -0.84914M 0.00754M -0.07551M
Total revenue 22.82M 22.18M 11.71M 8.95M 3.44M
Total operating expenses 28.75M 32.19M 22.74M 16.55M 15.45M
Cost of revenue 4.37M 5.94M 2.56M 2.01M 0.52M
Total other income expense net -0.28191M -0.31673M 0.87M 0.25M 0.61M
Discontinued operations - - - - -
Net income from continuing ops -10.58602M -16.27081M -12.68331M -9.34964M -15.46612M
Net income applicable to common shares -10.58602M -16.27081M -12.68331M -9.34964M -11.91200M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 9.21M 17.90M 12.46M 13.72M 23.64M
Intangible assets 0.83M 2.39M 2.41M 2.53M 2.33M
Earning assets - - - - -
Other current assets 0.34M - 0.54M 0.48M 0.45M
Total liab 5.77M 5.08M 4.42M 2.95M 4.73M
Total stockholder equity 3.44M 12.82M 8.04M 10.77M 18.91M
Deferred long term liab - - 1.37M 1.49M 1.37M
Other current liab 2.07M - 1.10M 0.77M 0.57M
Common stock 133.93M - 113.53M 102.92M 101.28M
Capital stock - 133.82M 113.53M 102.92M 101.28M
Retained earnings -89.09725M -78.51123M -63.12851M -50.44520M -41.09556M
Other liab - - 0.85M 1.30M 1.38M
Good will - - - - -
Other assets - - 0.04M 1.52M 1.41M
Cash 1.67M 9.24M 5.07M 7.00M 8.10M
Cash and equivalents - - - - -
Total current liabilities 3.22M 3.84M 2.61M 1.54M 3.23M
Current deferred revenue - - 0.27M 0.09M 1.91M
Net debt 0.82M - -3.85365M -6.72483M -7.81358M
Short term debt 0.22M - 0.26M 0.17M 0.17M
Short long term debt - - - - -
Short long term debt total 2.49M - 1.22M 0.28M 0.29M
Other stockholder equity - - -1.90588M -41.70931M -41.27291M
Property plant equipment - - 1.75M 0.92M 1.02M
Total current assets 6.05M 13.96M 8.26M 10.23M 20.25M
Long term investments - - - - -
Net tangible assets - - 6.99M 9.72M 17.95M
Short term investments - 0.04M 0.04M 0.37M 7.24M
Net receivables 3.31M 3.46M 1.74M 0.89M 3.39M
Long term debt - - - - -
Inventory 0.73M 0.72M 0.87M 1.50M 1.07M
Accounts payable 0.93M 1.41M 0.97M 0.52M 0.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -41.38735M - -42.36229M -41.70931M -41.27291M
Additional paid in capital - - - - -
Common stock total equity - - - - 131.50M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.26M - 0.04M 0.04M 0.04M
Deferred long term asset charges - - - - -
Non current assets total 3.16M 3.94M 4.20M 3.49M 3.39M
Capital lease obligations - 0.96M 1.22M 0.28M 0.37M
Long term debt total - - 0.96M 0.11M 0.12M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.58922M -0.88450M -0.47572M -0.71676M -0.89172M
Change to liabilities - - 0.53M -1.79967M 1.55M
Total cashflows from investing activities -0.58922M -0.88450M -0.47572M -0.71676M -0.68680M
Net borrowings 2.00M - -0.25323M -0.21276M -0.22261M
Total cash from financing activities 1.75M 20.11M 10.25M 1.43M 10.71M
Change to operating activities - - -0.38504M -0.05894M 0.00357M
Net income -10.58602M -23.87254M -11.83417M -9.34964M -11.30326M
Change in cash -7.56478M 4.17M -2.25658M -7.97140M -1.57120M
Begin period cash flow 9.24M 5.07M 7.37M 15.34M 16.91M
End period cash flow 1.67M 9.24M 5.11M 7.37M 15.34M
Total cash from operating activities -7.96340M -15.05900M -10.93707M -8.26435M -11.90664M
Issuance of capital stock - 21.02M 10.89M 1.65M 11.32M
Depreciation 1.27M 1.68M 0.90M 0.79M 0.70M
Other cashflows from investing activities -0.54290M -0.58905M - - -
Dividends paid - - - - -
Change to inventory 0.00465M 0.27M 0.56M -0.38936M -0.62952M
Change to account receivables 0.25M -1.90928M -0.80783M 2.50M -2.09705M
Sale purchase of stock 0.00259M -0.63786M -0.38563M -0.00623M -0.38774M
Other cashflows from financing activities -0.25070M -6.98320M -0.25323M -0.21276M -0.22261M
Change to netincome - - 0.10M 0.04M 0.47M
Capital expenditures 0.59M 0.88M 0.48M 0.72M 0.69M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.85M -2.18042M - -17.77699M -14.85707M
Stock based compensation 1.01M 0.20M - - -
Other non cash items -0.51052M 10.99M 10.94M 8.56M 11.00M
Free cash flow -8.55262M -15.94346M -11.41278M -8.98111M -12.59344M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NXS
Next Science Ltd		 - -% - - 128.21 1.92 3.18 1.56 -11.0461
AFP
Aft Pharmaceuticals Ltd		 - -% 3.00 23.08 19.88 1.35 3.81 1.72 13.67
VLS
Vita Life Sciences Ltd		 -0.02 0.80% 2.48 13.89 42.73 1.46 2.42 1.24 6.53
SNT
Syntara Ltd		 -0.001 3.33% 0.03 - 20.45 6.32 4.62 6.32 -2.1607
MVP
Medical Developments International Ltd		 0.005 1.23% 0.41 - 166.67 1.14 0.83 0.75 11.48

Reports Covered

Stock Research & News

View All

Profile

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Next Science Ltd

Australia Square, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Ms. Judith Mitchell M.B.A. MD, CEO & Exec. Director NA
Dr. Matthew Franco Myntti Founder & CTO NA
Ms. Jacqueline Butler CA (ICAEW) Chief Financial Officer NA
Mr. Jon Swanson Chief Operating Officer NA
Mr. Michael Morello VP of Sales NA
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD Company Sec. NA
Mr. Harry Thomas Hall MD, CEO & Director NA
Marc Zimmerman Chief Financial Officer NA
Mr. Robert Bell Senior Vice President of North American Sales NA
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.